Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Blog

Jack in the Box to Post Q2 Earnings: What's in Store for the Stock?
Jack in the Box to Post Q2 Earnings: What's in Store for the Stock?

Jack in the Box JACK is scheduled to report second-quarter fiscal 2025 results on May 14, after the closing bell. In the previous quarter, the company’s earnings surpassed the Zacks Consensus

Cenovus Energy Q1 Earnings Beat on Higher Upstream Production
Cenovus Energy Q1 Earnings Beat on Higher Upstream Production

Cenovus Energy Inc. CVE reported first-quarter 2025 adjusted earnings per share of 32 cents, which beat the Zacks Consensus Estimate of 29 cents. The bottom line, however, declined from the year-ago

Surgery Partners (SGRY) Q1 Earnings and Revenues Miss Estimates
Surgery Partners (SGRY) Q1 Earnings and Revenues Miss Estimates

Surgery Partners (SGRY) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.10 per share a year ago. These

Tariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock?
Tariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock?

Women’s health device maker, Hologic HOLX, slashed its earnings forecast for the full fiscal 2025, even as the latest second-quarter results topped expectations. The revenue target of $4.05-$4.10

3 Stocks With Upgraded Broker Ratings to Navigate Market Uncertainties
3 Stocks With Upgraded Broker Ratings to Navigate Market Uncertainties

Stock markets have been experiencing significant volatility of late. This is largely because of the ongoing tariff war, which has also led to expectations of economic slowdown and rising inflation

SelectQuote (SLQT) Misses Q3 Earnings and Revenue Estimates
SelectQuote (SLQT) Misses Q3 Earnings and Revenue Estimates

SelectQuote (SLQT) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.05 per share a year ago. These

Chegg (CHGG) Reports Q1 Loss, Tops Revenue Estimates
Chegg (CHGG) Reports Q1 Loss, Tops Revenue Estimates

Chegg (CHGG) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.26 per share a year ago. These figures are

HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up
HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up

Haemonetics Corporation HAE delivered fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.24, which rose 37.8% year over year. The bottom line topped the Zacks Consensus Estimate by

Walmart, Target and Amazon are part of Zacks Earnings Preview
Walmart, Target and Amazon are part of Zacks Earnings Preview

For Immediate Release

Chicago, IL – May 12, 2025 – Zacks.com releases the list of companies likely to issue earnings surprises. This week’s list includes Walmart WMT, Target TGT and Amazon AMZN.

ProAssurance Q1 Earnings Miss Estimates on Declining Premiums
ProAssurance Q1 Earnings Miss Estimates on Declining Premiums

Shares of ProAssurance Corporation PRA have remained relatively stable, falling only 0.3% since the company reported first-quarter 2025 results on May 6. The weaker-than-expected quarterly results

Advantage Solutions Inc. (ADV) Reports Q1 Loss, Misses Revenue Estimates
Advantage Solutions Inc. (ADV) Reports Q1 Loss, Misses Revenue Estimates

Advantage Solutions Inc. (ADV) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.16 per share a year ago. These figures are

Is the Options Market Predicting a Spike in Texas Instruments Stock?
Is the Options Market Predicting a Spike in Texas Instruments Stock?

Investors in Texas Instruments Incorporated TXN need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 20, 2025 $85 Call had some of the

Here's How Much You'd Have If You Invested $1000 in Broadcom Inc. a Decade Ago
Here's How Much You'd Have If You Invested $1000 in Broadcom Inc. a Decade Ago

How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors

Here's How Much a $1000 Investment in Leidos Made 10 Years Ago Would Be Worth Today
Here's How Much a $1000 Investment in Leidos Made 10 Years Ago Would Be Worth Today

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and

If You Invested $1000 in Netflix a Decade Ago, This is How Much It'd Be Worth Now
If You Invested $1000 in Netflix a Decade Ago, This is How Much It'd Be Worth Now

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and

Are Options Traders Betting on a Big Move in TripAdvisor Stock?
Are Options Traders Betting on a Big Move in TripAdvisor Stock?

Investors in Tripadvisor, Inc TRIP need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 20, 2025 $8 Call had some of the highest implied

Macerich (MAC) Q1 FFO and Revenues Top Estimates
Macerich (MAC) Q1 FFO and Revenues Top Estimates

Macerich (MAC) came out with quarterly funds from operations (FFO) of $0.33 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to FFO of $0.31 per share a year ago

NRG Energy (NRG) Beats Q1 Earnings and Revenue Estimates
NRG Energy (NRG) Beats Q1 Earnings and Revenue Estimates

NRG Energy (NRG) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $1.80 per share. This compares to earnings of $0.80 per share a year ago. These figures

Upwork and PACCAR have been highlighted as Zacks Bull and Bear of the Day
Upwork and PACCAR have been highlighted as Zacks Bull and Bear of the Day

For Immediate Release

Chicago, IL – May 12, 2025 – Zacks Equity Research shares Upwork UPWK as the Bull of the Day and PACCAR PCAR as the Bear of the Day. In addition, Zacks Equity Research provides

Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates

Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.35 per share a year ago. These

BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $1.50 per share versus the Zacks Consensus Estimate of a loss of $2.72. This compares to loss of $13.92 per share a year ago

Blade Air Mobility, Inc. (BLDE) Reports Q1 Loss, Tops Revenue Estimates
Blade Air Mobility, Inc. (BLDE) Reports Q1 Loss, Tops Revenue Estimates

Blade Air Mobility, Inc. (BLDE) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.06 per share a year ago. These

NRG Energy's Q1 Earnings Surpass Estimates, Revenues Rise Y/Y
NRG Energy's Q1 Earnings Surpass Estimates, Revenues Rise Y/Y

NRG Energy, Inc. NRG reported first-quarter 2025 earnings of $2.62 per share, which surpassed the Zacks Consensus Estimate of $1.80 by 45.6%. In the year-ago quarter, the company reported earnings

What Makes Prairie Operating Co. a Strong Buy Right Now?
What Makes Prairie Operating Co. a Strong Buy Right Now?

Prairie Operating Co. PROP made headlines with its $602 million acquisition of Bayswater assets, a move that has significantly altered its growth trajectory. The deal, which includes 24,000 net

J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study

J&J JNJ announced positive data from the phase III ICONIC-TOTAL study evaluating its investigational oral peptide, icotrokinra, for the treatment of plaque psoriasis (PsO) in patients with at least